Lifecare completes production-level compliance testing of implant electronics - moves to finalize CE claim

17 Feb 2026 07:00 CET

Bergen, Norway, 17 February 2026 - Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable Continuous Glucose Monitoring (CGM)
technology, today announces the successful completion of final compliance
testing of the electronics used in its implant system, marking a decisive
regulatory development.

The completed testing has been performed on electronics used in implants
manufactured under Lifecare's reproducible and quality-controlled production
protocol - the same structured batch currently deployed in the ongoing
longevity study (LFC-SEN-002) and planned deployed in Lifecares First-In-Human
study (pending approval) and for the commercial veterinary version.

Compliance testing of electronics used in the reproducible manufacturing batch
validates the electronics architecture at production level - not merely at
prototype stage. This confirms that the electronics platform underpinning the
Company's implant system is both regulatory compliant and manufacturing
robust.

The testing program builds on previously communicated electromagnetic (EMC)
and radio frequency (RF) compliance activities and includes verification of
the fully finalized system configuration.

All required laboratory testing has been successfully executed according to
applicable European standards. Lifecare is currently awaiting the final
consolidated test report from the accredited laboratory. Upon receipt,
Lifecare will finalize and sign the technical file required to formally claim
CE marking of the electronics module.

Importantly, the electronics configuration validated through this process is
the same architecture used in:

* The reproducible implant manufacturing batch,
* The implants currently deployed in the longevity study, and
* The first planned commercial veterinary product version.

No further design adjustments to the electronics are planned.

"Electronics used in implantable medical devices are subject to particularly
rigorous safety and reliability requirements. Unlike external devices, implant
electronics must operate safely inside the body over extended periods without
posing electrical, thermal or electromagnetic risk. Our electronics platform
meets the stringent standards required for implantable use, strengthening both
our regulatory position and our readiness for commercialization," says Joacim
Holter, CEO of Lifecare ASA.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

666007_Lifecare completes production-level compliance testing of implant electronics - moves to finalize CE claim.pdf